Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted - 04/11/16
Abstract |
Antifibrotic drugs for idiopathic pulmonary fibrosis patients in England and Scotland are only available to those with FVC percent predicted (FVC%pred) less than or equal to 80%. The prescribing guidance does not state which set of reference values should be used and we show that a patient's FVC%pred can change by 4–6% depending on the choice of reference. We calculated FVC%pred for a group of 528 IPF patients using three different sets of reference values. 90% of patients with FVC%pred 80–85% calculated using European Community Coal and Steel (ECSC) reference values fall into the eligible range when NHANES reference values are used.
Le texte complet de cet article est disponible en PDF.Highlights |
• | FVC percent predicted (FVC%pred) can be calculated using different reference values. |
• | FVC%pred<80% may determine patient eligibility for antifibrotics in IPF. |
• | FVC reference values often used in trials and clinical practice are ECSC, GLI and NHANES. |
• | ECSC FVC%pred usually falls by 4–6% when converted to NHANES FVC%pred. |
• | Most patients with ECSC FVC%pred 80–85% will have NHANES FVC%pred <80%. |
Keywords : Respiratory function tests, Idiopathic pulmonary fibrosis, Interstitial lung disease
Plan
Vol 120
P. 131-133 - novembre 2016 Retour au numéro
Article précédent
- Neurocognitive impairment is correlated with oxidative stress in patients with moderate-to-severe obstructive sleep apnea hypopnea syndrome
- Yanyu He, Rui Chen, Jing Wang, Wenying Pan, Yanqiu Sun, Fei Han, Qiaojun Wang, Chunfeng Liu
Déjà abonné à cette revue ?